ZURA BIO LIMITED APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ZURA BIO LIMITED (ZURA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.46M, a 19.43% increase year-over-year.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.01M, a 37.43% increase year-over-year.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.58M, a 8.52% decline year-over-year.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.38M, a 72.48% decline year-over-year.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.33M, a 26.59% decline from fiscal 2024.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.80M, a 28.63% increase from fiscal 2023.
- ZURA BIO LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.06M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 5 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 8 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 11 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.46M 10-Q · filed 2026-08-11 | $9.46M 10-Q · filed 2026-08-11 | $12.04M derived: sum of 3 quarters · filed 2026-08-11 | $14.42M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $5.01M 10-Q · filed 2026-05-07 | $7.58M derived: sum of 2 quarters · filed 2026-05-07 | $9.96M derived: sum of 3 quarters · filed 2026-05-07 | $13.70M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.96M derived: sum of 2 quarters · filed 2026-03-19 | $8.69M derived: sum of 3 quarters · filed 2026-08-11 | $12.33M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $2.38M 10-Q · filed 2025-11-13 | $6.11M derived: sum of 2 quarters · filed 2026-08-11 | $9.76M 10-Q · filed 2025-11-13 | $12.57M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $3.73M 10-Q · filed 2026-08-11 | $7.38M 10-Q · filed 2026-08-11 | $10.19M derived: sum of 3 quarters · filed 2026-08-11 | $18.84M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $3.64M 10-Q · filed 2026-05-07 | $6.46M derived: sum of 2 quarters · filed 2026-05-07 | $15.11M derived: sum of 3 quarters · filed 2026-05-07 | $18.03M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $11.46M derived: sum of 2 quarters · filed 2026-03-19 | $14.39M derived: sum of 3 quarters · filed 2026-03-19 | $16.80M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $8.65M 10-Q · filed 2025-11-13 | $11.57M derived: sum of 2 quarters · filed 2025-11-13 | $13.98M 10-Q · filed 2025-11-13 | $16.38M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $2.93M 10-Q · filed 2025-08-14 | $5.33M 10-Q · filed 2025-08-14 | $7.73M derived: sum of 3 quarters · filed 2025-08-14 | $10.31M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $2.41M 10-Q · filed 2025-05-08 | $4.80M derived: sum of 2 quarters · filed 2025-05-08 | $7.38M derived: sum of 3 quarters · filed 2025-05-08 | $15.29M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $4.97M derived: sum of 2 quarters · filed 2025-03-25 | $12.88M derived: sum of 3 quarters · filed 2025-03-25 | $13.06M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $2.58M 10-Q · filed 2024-11-07 | $10.48M derived: sum of 2 quarters · filed 2024-11-07 | $10.66M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | $7.91M 10-Q · filed 2024-08-13 | $8.09M 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | $180.00K 10-Q · filed 2024-05-09 | ||||||
| 2022-12-31 | $334.00K 10-K · filed 2024-03-28 | ||||||
| 2022-09-30 | $12.00K 10-Q · filed 2023-11-13 | $321.00K derived: sum of 2 quarters · filed 2023-11-13 | $321.00K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $309.00K 10-Q · filed 2023-08-14 | $309.00K 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |